
    
      SP0966 is a Phase 2, multicenter, open-label exploratory study designed to assess the safety
      and preliminary efficacy of oral lacosamide as adjunctive therapy for epilepsy syndromes
      associated with generalized seizures in pediatric subjects â‰¥1 month to <18 years of age.
    
  